AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Melexis N.V.

Earnings Release Aug 2, 2023

3975_ir_2023-08-02_6b66635f-35dd-4ec6-bda9-829d794f8e1a.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

Press release - Regulated Information

Melexis Q2 2023 results – Second quarter sales of 236.7 million EUR

Intermediate declaration by the Board of Directors

Ieper, Belgium – August 2nd , 2023, 07.00 hrs CET

CONFORM IFRS Q2 2023 Q2 2022 YOY change Q1 2023 SEQ change
in k EUR (%) (%)
Sales 236,650 208,408 +14% 228,602 +4%
Gross result 111,269 93,647 +19% 102,791 +8%
Gross Margin 47.0% 44.9% 45.0%
EBIT 67,502 57,258 +18% 61,071 +11%
EBIT in % 28.5% 27.5% 26.7%
EBITDA 79,022 69,499 +14% 72,322 +9%
EBITDA in % 33.4% 33.3% 31.6%
Net result 51,899 47,585 +9% 50,917 +2%
Net result per share (EPS) 1.28 1.18 1.26
CAPEX 20,917 9,436 18,175

Sales for the second quarter of 2023 were 236.7 million EUR, an increase of 14% compared to the same quarter of the previous year and an increase of 4% compared to the previous quarter.

The EUR/USD exchange rate evolution had a negative impact of 1% on sales compared to the same quarter of last year and a negative impact of 1% on sales compared to the previous quarter.

The gross result was 111.3 million EUR or 47.0% of sales, an increase of 19% compared to the same quarter of last year and an increase of 8% compared to the previous quarter.

R&D expenses were 10.9% of sales, G&A was at 5.1% of sales and Selling was at 2.4% of sales. The operating result was 67.5 million EUR or 28.5% of sales, an increase of 18% compared to the same quarter of last year and an increase of 11% compared to the previous quarter.

The net result was 51.9 million EUR or 1.28 EUR per share, an increase of 9% compared to 47.6 million EUR or 1.18 EUR per share in the second quarter of 2022 and an increase of 2% compared to the previous quarter.

CONFORM IFRS HY 2023 HY 2022 YOY change
in k EUR (%)
Sales 465,251 392,473 +19%
Gross result 214,060 176,793 +21%
Gross Margin 46.0% 45.0%
EBIT 128,573 107,118 +20%
EBIT in % 27.6% 27.3%
EBITDA 151,344 130,810 +16%
EBITDA in % 32.5% 33.3%
Net result 102,816 96,205 +7%
Net result per share (EPS) 2.54 2.38
CAPEX 39,092 15,621

Sales for the first half year of 2023 were 465.3 million EUR, an increase of 19% compared to the first half year of 2022.

The EUR/USD exchange rate evolution had no impact on sales compared to the first half year of 2022. The gross result was 214.1 million EUR or 46.0% of sales, an increase of 21% compared to the same period last year. R&D expenses were 10.8% of sales, G&A was at 5.2% of sales and Selling was at 2.3% of sales. The operating result was 128.6 million EUR or 27.6% of sales, an increase of 20% compared to 107.1 million EUR in the same half year of 2022.

The net result was 102.8 million EUR or 2.54 EUR per share, an increase of 7% compared to 96.2 million EUR or 2.38 EUR per share in the first half year of 2022.

Dividend

The Board of Directors decided to pay out an interim dividend of 1.30 EUR gross per share. The Melexis shares will start trading ex coupon on October 17, 2023 (opening of the market). The record date is October 18, 2023 (closing of the market) and the dividend will be payable as from October 19, 2023.

Outlook

Melexis expects sales in the third quarter of 2023 in the range of 245 to 250 million EUR.

For the full year 2023, Melexis now expects a sales increase between 14% and 16% (previously between 11% and 16%), with a gross profit margin of above 45% (previously around 45%) and an operating margin of around 27% (previously around 26%) at the midpoint of the sales guidance, all taking into account a EUR/USD exchange rate of 1.10 for the remainder of the year.

For the full year 2023, we expect CAPEX of around 100 million EUR (previously 70 million EUR).

Business comment – Marc Biron, CEO:

"With 236.7 million EUR, Melexis achieved a year-over-year sales increase of 14% in the second quarter of 2023, landing at the higher end of the guidance. As we have been able to realize a steady sequential growth, we are increasing our full-year sales and profit guidance. Furthermore, we now expect higher capital expenditures than forecasted at the start of 2023, mainly as a result of the swift execution of the construction of our new probing facility in Malaysia.

Current sensors, embedded motor drivers, magnetic sensors and embedded lighting were the bestperforming product lines in the first half of 2023, reflecting our success in both electric powertrain and body, chassis and safety applications. Some examples of applications benefiting from those products include inverters and thermal valves in electric vehicles as well as applications independent of the powertrain, such as electric air vents, air conditioning flaps, electric brakes and interior ambient lighting.

We launched a new embedded motor driver that improves thermal and expansion valves in electric vehicles, extending their range. We also unveiled a time-of-flight sensor for safety applications such as dynamic airbag deployment and driver attention monitoring.

Sales to automotive customers represented 91% of total sales, in the second quarter as well as in the first half of 2023. The portion of standard product (ASSPs) sales represented 75% of total sales in the second quarter and 76% of total sales in the first half of 2023.

Looking beyond 2023, our opportunity pipeline and design wins are growing steadily in all product lines. We have the right technologies to support the journey towards a more sustainable, safer and healthier future."

The statutory auditor, PwC Bedrijfsrevisoren BV / Reviseurs d'Entreprises SRL, represented by Griet Helsen, has confirmed that the review of the Consolidated Income Statement, the Consolidated Statement of Financial Position and the Consolidated Statements of Cash Flow as per June 30, 2023, is substantially completed and concluded that to date, based on the review, nothing has come to the attention that causes them to believe that the Consolidated Income Statement, the Consolidated Statement of Financial Position and the Consolidated Statements of Cash Flow is not prepared, in all materials respects, in accordance with IAS 34, as adopted by the European Union.

Financial Calendar

  • Dividend pay date: October 19, 2023 (ex coupon on October 17, 2023)
  • Publication Q3 Results 2023: October 25, 2023 (at 7 hrs CET)
  • Capital Markets Day: November 14, 2023
  • Publication FY 2023 Results: February 7, 2024 (at 7 hrs CET)

The company's results will be discussed in a conference call and an audiocast on Wednesday, August 2nd , 2023 at 10:30 hrs CET.

To register for the conference call (possibility to ask questions)

The conference call will be in English. You have to register for this conference call in advance. You can register by clicking here and filling out the requested information. After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes, all participants must register individually if they wish to join the call.

To register for the audiocast (no possibility to ask questions)

To register for the audiocast, click here.

For more information: Investor Relations Email: [email protected]

About Melexis

Combining a passion for technology with truly inspired engineering, Melexis designs, develops and delivers innovative micro-electronic solutions that enable designers to turn ideas into applications that support the best imaginable future. The company's advanced mixed-signal semiconductor sensor and actuator components address the challenges of integrating sensing, driving and communication into next-generation products and systems that improve safety, raise efficiency, support sustainability and enhance comfort. Melexis is headquartered in Belgium and employs approximately 1,900 people in 12 countries. The company is publicly traded on Euronext Brussels (MELE). For more information, visit www.melexis.com

Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forwardlooking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.

Consolidated Income Statement

CONFORM IFRS Quarter ended Quarter ended Half Year ended Half Year ended Year ended
30/06/2023 30/06/2022 30/06/2023 30/06/2022 31/12/2022
in k EUR audited
Sales 236,650 208,408 465,251 392,473 836,157
Cost of sales -125,381 -114,761 -251,191 -215,680 -461,479
Gross result 111,269 93,647 214,060 176,793 374,679
R&D -25,847 -22,139 -50,468 -42,546 -90,211
G&A -12,138 -10,278 -24,291 -19,494 -40,887
Selling -5,780 -3,972 -10,727 -7,635 -17,052
Other operating result
Operating result (EBIT) 67,502 57,258 128,573 107,118 226,528
Financial result -3,298 502 -2,320 10,210 11,851
Result before taxes 64,204 57,760 126,253 117,327 238,379
Income taxes -12,305 -10,175 -23,437 -21,122 -41,226
Net result 51,899 47,585 102,816 96,205 197,153
Net result per share in EUR 1.28 1.18 2.54 2.38 4.88

Consolidated Statement of Financial Position

CONFORM IFRS Half Year ended
30/06/2023
Half Year ended
30/06/2022
Year ended
31/12/2022
in k EUR audited
Current Assets :
Cash and cash equivalents 35,710 39,270 85,080
Current investments 0 23,394 12,501
A/R Trade 133,069 100,710 107,547
A/R from related parties 1,253 1,059 1,286
Assets for current tax 581 10,729 1,594
Other current assets 22,248 18,881 20,079
Inventories 212,759 167,293 179,649
Total current assets 405,620 361,335 407,735
Non-current assets :
Property, plant and equipment 155,786 129,133 135,079
Leased assets 3,738 4,143 4,168
Intangible fixed assets 2,514 3,669 3,049
Other non-current assets 141,513 2,927 2,369
Deferred tax assets 29,736 21,459 27,832
Total non current assets 333,286 161,332 172,498
Total assets 738,906 522,667 580,233

CONFORM IFRS Half Year ended Half Year ended Year ended
30/06/2023 30/06/2022 31/12/2022
in k EUR
Liabilities and shareholders Equity
audited
Current liabilities :
Derivative financial instruments 359 943 0
Lease liabilities 894 917 1,710
A/P trade 31,360 23,424 28,728
Affiliated companies 33,895 28,320 26,195
Accrued taxes 3,571 3,197 1,284
Short-term employee benefits accruals 17,767 14,783 21,104
Other current liabilities 7,600 6,481 5,106
Deferred income 4,795 2,738 3,953
Total current liabilities 100,241 80,804 88,079
Non current liabilities :
LT debt less current portion 134,968 0 0
Lease liabilities 2,910 3,295 2,539
Deferred tax liabilities 125 0 3,260
Other non-current liabilities 4,904 4,148 4,272
Total non current liabilities 142,907 7,443 10,071
Shareholders' equity :
Shareholders' capital 565 565 565
Legal reserve 57 57 57
Retained earnings 396,362 340,609 288,089
Current period's profit 102,816 96,205 197,153
Cumulative translation adjustment -4,041 -3,015 -3,780
Equity attributable to company owners 495,758 434,420 482,083
Non controlling interests 0 0 0
Total shareholders equity 495,758 434,420 482,083
Total liabilities, shareholders' equity
and minority interests
738,906 522,667 580,233

Consolidated Statements of Cash Flow

CONFORM IFRS Quarter ended Quarter ended Half Year ended Half Year ended Year ended
30/06/2023 30/06/2022 30/06/2023 30/06/2022 31/12/2022
(in k EUR) audited
Cash flow from operating activities
Net income 51,899 47,585 102,816 96,205 197,153
Adjustments for : 0 0 0
Operating activities 27,413 25,679 49,273 42,946 82,227
Depreciation and amortisation 11,108 11,785 21,845 22,782 43,324
Depreciation leased assets 412 455 926 911 1,843
Other provisions 162 148 631 4,148 4,272
Deferred income 848 1,241 843 1,243 1,515
Unrealized financial result -2,084 314 1,010 -9,287 1,320
Financial result 4,662 1,561 580 2,027 -11,273
Income tax expense/income 12,305 10,175 23,437 21,122 41,226
Operating profit before working capital changes 79,311 73,264 152,089 139,150 279,380
A/R, Trade -3,259 -6,510 -25,599 -20,478 -27,324
A/R, affiliates -2 102 33 4,121 3,894
Other current assets -2,971 -4,058 -2,201 -8,730 -8,613
Other non current assets -139,389 157 -139,143 213 771
Inventories -23,194 -11,207 -36,826 -26,411 -40,380
A/P -3,101 -3,376 2,678 737 6,057
A/P affiliates 7,830 5,470 7,700 8,535 6,410
Employee benefit liabilities -8,232 -6,770 -3,311 -3,031 3,311
Other current liabilities 2,499 1,087 2,585 2,524 932
Cash generated from operations -90,506 48,159 -41,995 96,630 224,438
Interest paid -1,185 -32 -1,215 -59 -112
Income tax paid -3,087 -1,013 -25,191 -19,159 -36,489
Cash flow from operating activities -94,778 47,115 -68,401 77,413 187,837
0 0
Cash flow from investing activities
Purchase of PPE and intangible assets (netted) -20,917 -9,436 -39,092 -15,621 -39,884
Interest received 494 1 657 2 50
Investments/proceeds/ from current investments 11,945 0 11,629 0 12,543
Cash provided from investing activities -8,478 -9,435 -26,807 -15,618 -27,290
Cash flows from financing activities
Proceeds/Repayment of long-and short-term debt 134,968 0 134,968 0 0
Repayment leasings 59 -455 -371 -884 -1,841
Impact of exchange results on financing items -148 -3,266 550 -4,088 -3,519
Dividend payment -88,880 -52,520 -88,880 -52,520 -105,040
Cash provided from financing activities 45,999 -56,240 46,267 -57,492 -110,401
0 0 0
Effect of exchange rate changes on cash and cash equivalents -293 30 -429 17 -16
Increase/decrease in cash and cash equivalents -57,550 -18,530 -49,370 4,319 50,130
Cash at beginning of the period 93,259 57,799 85,080 34,950 34,950
Cash at the end of the period 35,710 39,270 35,710 39,270 85,080

Sales per Geography

Q2 2023 Q2 2022 HY 2023 HY 2022 FY 2022
APAC
Asia Pacific
58% 57% 57% 58% 59%
EMEA
Europe - Middle-East - Africa
30% 32% 32% 31% 30%
NALA
North America - Latin America
12% 11% 11% 11% 11%
TOTAL 100% 100% 100% 100% 100%

Talk to a Data Expert

Have a question? We'll get back to you promptly.